Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

Taming CAR T cell therapy toxicity

Nature Materials volume 22, pages 1444–1445 (2023)Cite this article

Subjects

Post-infusion poly(ethylene glycol) surface modification of chimeric antigen receptor (CAR)-engineered T cells and a subcutaneous chemokine-adsorbing hydrogel address cytokine release syndrome and the neurotoxicity side effects of CAR T cell therapy against tumours.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Solutions to mitigate the side effects of CAR T cell therapy, administered before or after CAR T cell infusion.

References

  1. Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Nat. Rev. Immunol. 22, 85–96 (2022).

    Article  CAS  Google Scholar 

  2. Lee, D. W. et al. Blood 124, 188–195 (2014).

    Article  CAS  Google Scholar 

  3. Norelli, M. et al. Nat. Med. 24, 739–748 (2018).

    Article  CAS  Google Scholar 

  4. Giavridis, T. et al. Nat. Med. 24, 731–738 (2018).

    Article  CAS  Google Scholar 

  5. Choy, E. H. et al. Nat. Rev. Rheumatol. 16, 335–345 (2020).

    Article  CAS  Google Scholar 

  6. Park, J. H. et al. N. Engl. J. Med. 378, 449–459 (2018).

    Article  CAS  Google Scholar 

  7. Gong, N. et al. Nat. Mater. https://doi.org/10.1038/s41563-023-01646-6 (2023).

    Article  Google Scholar 

  8. Li, X. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01084-4 (2023).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Chuang Liu & Khalid Shah

  2. Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Chuang Liu & Khalid Shah

  3. Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA

    Khalid Shah

Authors
  1. Chuang Liu
    View author publications

    Search author on:PubMed Google Scholar

  2. Khalid Shah
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Khalid Shah.

Ethics declarations

Competing interests

K.S. owns equity in and is a member of the Board of Directors of AMASA Therapeutics, a company developing stem cell-based therapies for cancer. K.S.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. C.L. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, C., Shah, K. Taming CAR T cell therapy toxicity. Nat. Mater. 22, 1444–1445 (2023). https://doi.org/10.1038/s41563-023-01742-7

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41563-023-01742-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research